OOIR: Observatory of International Research

Papers

(The median citation count of American Journal of Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Issue Information	476
	267
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	246
CORRIGENDUM	157
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	152
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	147
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	145
	132
The latest insights into rare blood disorders: Diagnosis and treatment strategies	114
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	92
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	90
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	88
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	84
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	84
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	78
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	71
Teclistamab in patients with multiple myeloma and impaired renal function	71
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	70
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	67
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	66
Are veterans at increased risk of myeloproliferative neoplasms?	64
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	64
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	61
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	60
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	60

Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	60
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	57
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	57
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	56
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	54
Ruxolitinib for refractory large granular lymphocyte leukemia	50
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	49
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	48
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	48
Clonal Hematopoiesis and Thrombosis	48
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	48
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	48
Acute thrombocytopenia suggesting thrombotic microangiopathy	48
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	47
Molecular and clinicopathologic characterization of pediatric histiocytoses	46
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	46
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	45
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	45
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	44
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	44
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	44
Table of Contents	42
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	42
	40
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	39
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	38
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	37
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	37
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	36
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	35
International Consensus Classification for myeloid neoplasms at‐a‐glance	35
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	35
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma	35
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	35
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	35
Novel, de novo, beta‐globin variant with decreased oxygen affinity (HBB:c.317T>A, “Hemoglobin St. George”) in a healthy child with low oxygen saturations and ane	34
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	34
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	33
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	32
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	32
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	32
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	32
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	31
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	31
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation	31
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	31
Toward an improved understanding of hypomethylating agent and venetoclax therapies	31
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	31
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	31
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	30

Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	30
Hydroxyurea in pregnancy: Reframing the conversation	30
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	30
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	29
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	29
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β⁰ Thalassemia Major Patient	29
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	29
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	28
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	28
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	28
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	28
ERRATUM	28
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	28
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	28
The Diversity of Spiculated Erythrocytes	28
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	28
Issue Information	28
Prognostic impact of KMT2A‐AFF1‐positivity in 926 BCR‐ABL1‐negative B‐lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials sin	27
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	27
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	27
Elevated MCHC reveals a Southeast Asian Ovalocytosis	27
The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study	27
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes	27
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	27
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	26
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	26
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	26
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	26
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	26
Primary myelofibrosis in a patient with sickle cell disease	25
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	25
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	25
Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer	25
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia	25
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia	25
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	25
A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia	25
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	25
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	25
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma	25
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	24
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	24
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	24
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	23
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	23
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	23
Pearson syndrome	23
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B‐Cell Lymp	23
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	23
LLM Abstracts Supplement	23
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	23
Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma	23
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	22
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	22
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	22
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	22
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	22
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	22
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	22
Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients	22
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis	22
Table of Contents	21
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	21
Issue Information	21
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	21
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	21
	21
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	21
Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation	20
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	20
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	20
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	20
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	20
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	19
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	19
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	19
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	19
SARS‐CoV‐2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor	19
The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	19
Unusual complications in the management of chronic lymphocytic leukemia	19

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study	19
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma	19
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey	19
Disseminated coccidioidomycosis in bone marrow	19
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	19
2025 update on clinical trials in immune thrombocytopenia	19
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia	18
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	18
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	18
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	18
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated mult	18
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	18
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	18
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	18
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	18
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	18
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	18
‘Phenoconversion’ in adult patients with β‐thalassemia	17
Table of Contents	17
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	17
Space anemia unexplained: Red blood cells seem to be space‐proof	17
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma	17
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	17
RETRACTION: A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation	17
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	17
High incidence of malaria in patients with sickle cell disease	17
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	17
A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival	17
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	17
Issue Information	17
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa	17
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	17
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	16
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	16
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	16
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study	16
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	16
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	16
Peripheral blood evidence of iron overload	16
Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank	16
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	16
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	16
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	16
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase	16
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies	16
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study	16
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	16
Complement biology for hematologists	15
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	15
Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology	15
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	15
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	15
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	15
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	15
Hyperparathyroidism and the Hematologist	15
Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features	15
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan	15
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	15
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	15
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	15
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	15
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	15
Crystal‐storing lymphocytosis	14
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	14
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	14
Thalassemia enters a new age … And more lies ahead	14
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	14
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	14
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	14
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	14
Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis	14
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review	14
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	14
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7‐targeted Chimeric Antigen R	14
	14
	14
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	14
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	14
	14
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring	14
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study	14
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis”	14
	14
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	14
	14
Issue Information	14
Issue Information	13
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	13
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	13
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	13
CD19‐negative relapse in adult patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia following treatment with blinatumomab‐a post hoc analysis	13
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	13
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	13
Issue Information	13
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targeting	13